Loading…
Loading…
VKTX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VKTX and 80,000+ other tickers.
See exactly how VKTX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VKTX and 80,000+ other tickers.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal…
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Viking Therapeutics has significant upside potential based on Wall Street targets. VK2735's dual-formulation strategy could differentiate it in a crowded obesity drug market, but it faces major risks, including strong competition and safety concerns with the oral formulation.
Jupiter Topco LLC acquired a new stake in Viking Therapeutics, Inc. (NASDAQ: VKTX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 45,700 shares of the biotechnology company's stock, valued at approximately $1,783,000. Other hedge funds and other institutional investors
AXQ Capital LP grew its stake in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) by 164.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 91,437 shares of the biotechnology company's stock after buying an additional 56,796 shares during the quarter. AXQ Capital
Viking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% move from the prior day.